Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).
The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience.